10-Q: Bio-Path Holdings Faces Liquidity Crisis, Pauses Operations

Bio-Path Holdings reported a significant accumulated deficit and $0 cash, leading to an operational pause and employee furloughs, while continuing to seek critical financing.

Summary

• Reported $0 cash as of September 30, 2025, a significant decrease from $1.173 million at December 31, 2024.
• Accumulated deficit reached $126.0 million as of September 30, 2025, compared to $117.5 million at December 31, 2024.
• Net loss for the nine months ended September 30, 2025, was $8.4 million, an increase from $7.1 million for the same period in 2024.
• Implemented a company-wide operational pause on June 24, 2025, and furloughed most employees to conserve capital.
• March 2025 Promissory Notes were in default as of September 30, 2025, incurring a $0.1 million penalty, and the April 2025 Promissory Note defaulted subsequently.
• Nasdaq delisted the company's common stock on February 14, 2025, with trading commencing on the OTCQB Venture Market on February 19, 2025.
• Engaged Steel Giants Advisors LLC (SGA) on October 24, 2025, to advise on restructuring and capital raising.
• Issued 2 million common stock purchase warrants to SGA on January 2, 2026, and 51 shares of newly created Series S Preferred stock to SGA on January 3, 2026, for restructuring and domestication.
• New promissory notes totaling $76,800 in principal were issued on January 8, 2026, to the First and Second Lenders.

Sentiment

Score: 1

Explanation: The company is in severe financial distress, evidenced by $0 cash, a significant accumulated deficit, operational pause, employee furloughs, and multiple debt defaults. While some clinical data is positive, the company's ability to continue operations and fund development is highly uncertain, leading to a very negative sentiment.

Positives

• Prexigebersen (BP1001) Phase 2 AML trial showed promising interim data: 75% complete remission (CR/CRh/CRi) in 20 evaluable newly diagnosed AML patients and 55% CR/CRi/CRh in 23 evaluable relapsed/refractory AML patients.
• BP1001-A preclinical studies demonstrated potential as a treatment for obesity by attenuating fatty acid-induced insulin resistance and restoring insulin sensitivity in cell models.
• Safety run-in for the triple combination of prexigebersen, decitabine, and venetoclax in Phase 2 AML study was successfully completed with no dose-limiting toxicities attributed to prexigebersen.

Negatives

• Cash balance depleted to $0 as of September 30, 2025.
• Accumulated deficit increased to $126.0 million.
• Net loss for the nine months ended September 30, 2025, increased to $8.4 million.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Operational pause and furlough of most employees indicate severe financial distress.
• March 2025 Promissory Notes defaulted, incurring a $0.1 million penalty, and the April 2025 Promissory Note also defaulted.
• Common stock was delisted from Nasdaq, moving to the OTCQB Venture Market.
• Phase 1 clinical trial for BP1002 in refractory/relapsed lymphoma and CLL was discontinued due to enrollment challenges and a crowded development landscape.
• Disclosure controls and procedures were deemed not effective due to the operational pause and employee furloughs.

Risks

• Lack of significant revenue to date, history of recurring operating losses, and expectation of future operating losses.
• Need for substantial additional capital and the risk of delaying, reducing, or eliminating drug development and commercialization efforts if unable to raise additional capital.
• Highly competitive nature of the pharmaceutical and biotechnology industry.
• Risks that clinical trials may be delayed or terminated.
• Inability to obtain domestic and/or foreign regulatory approval for drug candidates.
• Reliance on third parties to conduct clinical trials and for manufacturing clinical drug supplies.
• Volatility of the trading price of common stock and the common stock being thinly traded.
• Operational pause, employee furloughs, or other cash conservation actions may result in unintended consequences and costs, such as loss of institutional knowledge, attrition, decreased morale, and difficulty pursuing new opportunities.
• Inability to maintain effective internal controls over financial reporting.

Future Outlook

The company expects to continue incurring significant operating expenses for the foreseeable future, particularly for clinical trials, manufacturing, and regulatory approval of its drug candidates. Substantial additional capital will be required to fund projected operating requirements, and there is no assurance that such capital will be available on favorable terms or at all. The company may be forced to reduce spending, extend payment terms, or suspend/curtail planned programs if funding is not secured. Profitability is dependent on successful development, regulatory approval, and commercialization of drug candidates, or entering into license/development agreements.

Management Comments

• We expect to continue to incur significant operating expenses for the foreseeable future in connection with its ongoing activities, including conducting clinical trials, manufacturing development and seeking regulatory approval of its drug candidates, prexigebersen, BP1002, BP1003 and BP1001-A.
• Accordingly, the Company will continue to require substantial additional capital to fund its projected operating requirements.
• There can be no assurance that the Company will be able to continue to raise additional capital through the sale of securities in the future.
• If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers and/or suspend or curtail planned programs.
• The Board is currently discussing and evaluating a course of action in light of the Companys limited capital resources, such operational pause and the resignations of Peter H. Nielsen, Heath Cleaver and Aline Sherwood.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industry, specifically in oncology and obesity-focused RNAi nanoparticle drug development. The discontinuation of the BP1002 trial for lymphoma/CLL due to a 'crowded development landscape' highlights the intense competition and the need for differentiated or superior therapies. The FDA's approval of venetoclax combinations for AML has shifted the treatment landscape, which Bio-Path aims to leverage by adding prexigebersen to existing combination therapies. The focus on molecular biomarkers is a growing trend in cancer development to improve treatment success rates. The shift towards obesity research with BP1001-A indicates an attempt to diversify the pipeline into another high-need area.

Comparison to Industry Standards

• The company's financial position, with $0 cash and a significant accumulated deficit, is far below industry standards for a clinical-stage biotech, which typically require substantial cash reserves to fund R&D.
• The delisting from Nasdaq to OTCQB indicates a failure to meet listing standards, which is a negative signal compared to peers on major exchanges.
• The discontinuation of a Phase 1 trial due to 'enrollment challenges' and a 'crowded development landscape' for BP1002 in lymphoma/CLL suggests the drug candidate may not have offered sufficient differentiation or competitive advantage against existing or developing therapies from larger, better-funded companies.
• The promising interim data for prexigebersen in AML (75% CR/CRh/CRi in newly diagnosed, 55% in relapsed/refractory) could be competitive if sustained, but without specific benchmarks from comparable trials or drugs, a direct assessment is difficult. For example, venetoclax in combination with decitabine/azacytidine has shown high response rates in AML, so prexigebersen would need to demonstrate superior efficacy or safety to stand out.
• The median survival of less than three months for AML patients relapsed from frontline venetoclax-based treatment highlights a critical unmet need that BP1002 aims to address, potentially offering a valuable alternative if successful.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant negative impact due to delisting, substantial accumulated deficit, operational pause, and dilution risk from future capital raises and convertible debt. The stock is thinly traded and volatile.
• Employees: Most employees furloughed due to the operational pause, leading to job insecurity and potential loss of talent.
• Creditors: Promissory notes have defaulted, indicating risk of non-payment, though conversion options exist.
• Patients/Clinical Trial Participants: Pausing of clinical trials for BP1001 and BP1001-A could delay access to potential treatments. Discontinuation of BP1002 trial for lymphoma/CLL means no further development for that indication.
• Suppliers: Company may extend payment terms with suppliers due to cash flow constraints.

Next Steps

• Seek additional funding through debt financings and public or private equity offerings.
• Potentially enter into collaborations and license arrangements for drug candidates.
• Complete the remaining IND enabling study for BP1003.
• Continue efforts to identify patients with a genetic profile more likely to respond to prexigebersen treatment through a molecular biomarker package.
• Restructure operations and financial obligations with the help of Steel Giants Advisors LLC.
• Manage current and planned corporate actions, including domestication in Wyoming.
• Make payments on new promissory notes starting June 30, 2026.

Key Dates

Recommendation

The company is in a dire financial state with $0 cash, a substantial accumulated deficit, and significant doubt about its ability to continue as a going concern. The operational pause, employee furloughs, delisting from Nasdaq, and multiple debt defaults signal extreme financial distress and operational instability. While some clinical data shows promise, the company's ability to fund further development is highly uncertain. The engagement of restructuring advisors and issuance of new high-interest debt and warrants further underscore the precarious situation and high risk of significant shareholder dilution or even bankruptcy. This presents an exceptionally high-risk investment with a strong likelihood of further value erosion.

Keywords

Oncology, RNAi nanoparticle, Drug development, AML, Obesity, Prexigebersen, BP1001, BP1002, BP1003, BP1001-A, Clinical trials, Biotechnology, Financial distress, Going concern, Capital raise, Delisting, Promissory notes default, Corporate governance, SEC filing, 10-Q